Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

C3N-01842

· cohortA3

8c941041-7446-577b-905b-280c7eb425b6

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype
cohortA3
subtype
cohortA3
age_years
69.88911704

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • SPERMATOGENESIS+0.300
  • PROTEIN_SECRETION+0.270
  • UV_RESPONSE_DN+0.250
  • G2M_CHECKPOINT+0.220
  • ANGIOGENESIS+0.200
  • ANDROGEN_RESPONSE+0.190
  • E2F_TARGETS+0.190
  • TGF_BETA_SIGNALING+0.080
  • KRAS_SIGNALING_UP+0.070
  • MYC_TARGETS_V1+0.070

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.490
  • INTERFERON_GAMMA_RESPONSE-0.430
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
  • ALLOGRAFT_REJECTION-0.370
  • NOTCH_SIGNALING-0.340
  • P53_PATHWAY-0.340
  • ADIPOGENESIS-0.320
  • MYC_TARGETS_V2-0.300
  • APICAL_SURFACE-0.290
  • APICAL_JUNCTION-0.280

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1b503bcc9-714d-40aa-8709-3b4577ce8007
colon-landscapes@1
0.796
2AUR-AFSP-TTM1-A-8-0-R-A741-41
breast-umap@18
D0.770
3s0122214
melanoma-umap@29
0.757
4C3N-01016
lung-landscapes@6
cohortA30.754
5MBCProject_2346_T1_RNA
breast-umap@18
B0.745
6R259
bladder-landscape@3
0.738
7SRR2932838
head-neck@1
0.734
8ERR2208889
melanoma-umap@29
0.729
9MNG640
mng-umap@100
0.729
10SRR12475135
colon-landscapes@1
0.728

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 16 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
SPERMATOGENESIS0.300Inavolisib— uncovered
PROTEIN_SECRETION0.270Remibrutinib— uncovered
UV_RESPONSE_DN0.250Inavolisib— uncovered
G2M_CHECKPOINT0.220Inavolisib— uncovered
ANGIOGENESIS0.200Remibrutinib— uncovered
ANDROGEN_RESPONSE0.190Inavolisib— uncovered
E2F_TARGETS0.190Inavolisib— uncovered
TGF_BETA_SIGNALING0.080Inavolisib— uncovered
KRAS_SIGNALING_UP0.070Inavolisib— uncovered
MYC_TARGETS_V10.070Inavolisib— uncovered
MITOTIC_SPINDLE0.060Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.050Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.040Inavolisib— uncovered
HYPOXIA0.040Idelalisib— uncovered
DNA_REPAIR0.030Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.010Inavolisib— uncovered